Skip to main content
Erschienen in: Journal of Endocrinological Investigation 8/2017

01.08.2017 | Original Article

The association between polycystic ovary syndrome, obesity, and the serum concentration of adipokines

verfasst von: S. Behboudi-Gandevani, F. Ramezani Tehrani, R. Bidhendi Yarandi, M. Noroozzadeh, M. Hedayati, F. Azizi

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to investigate the interactive effect of polycystic ovary syndrome (PCOS) status and obesity status on the serum levels of adipokines.

Methods

In this comparative case–control cross-sectional study, 58 women with PCOS and 104 eumenorrheic non-hirsute women as the control group were recruited. They were further divided into two subgroups of overweight/obese and normal weight. The interactive effect of the PCOS status and obesity status on the circulating levels of adipokines was assessed using general linear model with the adjustment of age.

Results

A statistically significant negative interaction was reported between obesity status and PCOS status in the determination of serum adiponectin and resistin concentrations (effect size = −0.14, interaction P = 0.001, effect size = −0.15, P = 0.016). It indicated that adiponectin and resistin were significantly decreased in overweight/obese patients with PCOS compared with other subgroups. Statistically significant positive interactive effects were found between PCOS status obesity status and leptin (effect size = 0.321, interaction P = 0.036), indicating that the overweight/obese women with PCOS had the higher levels of leptin compared with the control group. Also, no interaction was reported between PCOS status and obesity status with regard to the serum levels of other adipokines.

Conclusions

While no sufficient evidence is available with regard to the causal association between adipokines and PCOS, they may contribute to the development of PCOS and regarded as the novel biomarkers of PCOS.
Literatur
1.
Zurück zum Zitat Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, Farahmand M, Bahri Khomami M, Noroozzadeh M et al (2016) Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol 32:343–353CrossRefPubMed Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, Farahmand M, Bahri Khomami M, Noroozzadeh M et al (2016) Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol 32:343–353CrossRefPubMed
2.
Zurück zum Zitat Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F (2011) The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 9:39CrossRefPubMedPubMedCentral Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F (2011) The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 9:39CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lim SS, Davies MJ, Norman RJ, Moran LJ (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 18:618–637CrossRefPubMed Lim SS, Davies MJ, Norman RJ, Moran LJ (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 18:618–637CrossRefPubMed
4.
Zurück zum Zitat Çakıroğlu Y, Vural F, Vural B (2016) The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J Endocrinol Invest 39:899–907CrossRefPubMed Çakıroğlu Y, Vural F, Vural B (2016) The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J Endocrinol Invest 39:899–907CrossRefPubMed
5.
Zurück zum Zitat Durmus U, Duran C, Ecirli S.(2016) Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest 12:1–11 Durmus U, Duran C, Ecirli S.(2016) Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest 12:1–11
7.
Zurück zum Zitat Rolland YM, Haren MT, Patrick P, Banks WA, Malmstrom TK, Miller DK, Morley JE (2007) Adiponectin levels in obese and non-obese middle-aged African-American women. Obes Res Clin Pract 1:1–78CrossRefPubMedCentral Rolland YM, Haren MT, Patrick P, Banks WA, Malmstrom TK, Miller DK, Morley JE (2007) Adiponectin levels in obese and non-obese middle-aged African-American women. Obes Res Clin Pract 1:1–78CrossRefPubMedCentral
9.
Zurück zum Zitat Mendonca H, Montenegro Junior R, Foss M, Silva de Sá M, Ferriani R (2004) Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome. Braz J Med Biol Res 37:729–736CrossRefPubMed Mendonca H, Montenegro Junior R, Foss M, Silva de Sá M, Ferriani R (2004) Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome. Braz J Med Biol Res 37:729–736CrossRefPubMed
10.
Zurück zum Zitat Huang R, Yue J, Sun Y, Zheng J, Tao T, Li S et al (2015) Increased serum chemerin concentrations in patients with polycystic ovary syndrome: Relationship between insulin resistance and ovarian volume. Clin Chim Acta 450:6–369CrossRef Huang R, Yue J, Sun Y, Zheng J, Tao T, Li S et al (2015) Increased serum chemerin concentrations in patients with polycystic ovary syndrome: Relationship between insulin resistance and ovarian volume. Clin Chim Acta 450:6–369CrossRef
11.
Zurück zum Zitat Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H et al (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76:24–29CrossRefPubMed Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H et al (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76:24–29CrossRefPubMed
12.
Zurück zum Zitat Yang R-Z, Lee M-J, Hu H, Pray J, Wu H-B, Hansen BC et al (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290:E1253- 61CrossRefPubMed Yang R-Z, Lee M-J, Hu H, Pray J, Wu H-B, Hansen BC et al (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290:E1253- 61CrossRefPubMed
13.
Zurück zum Zitat Miyamoto Y, Morisaki H, Kokubo Y, Yamanaka I, Tomoike H, Okayama A, Yoshimasa Y, Morisaki T (2009) Resistin gene variations are associated with the metabolic syndrome in Japanese men. Obes Res Clin Pract 3:I–IICrossRef Miyamoto Y, Morisaki H, Kokubo Y, Yamanaka I, Tomoike H, Okayama A, Yoshimasa Y, Morisaki T (2009) Resistin gene variations are associated with the metabolic syndrome in Japanese men. Obes Res Clin Pract 3:I–IICrossRef
14.
Zurück zum Zitat Polak K, Czyzyk A, Simoncinin T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 2017; 40:1–8CrossRefPubMed Polak K, Czyzyk A, Simoncinin T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 2017; 40:1–8CrossRefPubMed
15.
Zurück zum Zitat Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC et al (2009) Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 15:297–307CrossRefPubMed Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC et al (2009) Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 15:297–307CrossRefPubMed
16.
Zurück zum Zitat Drolet R, Bélanger C, Fortier M, Huot C, Mailloux J, Légaré D et al (2009) Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity 17:424–430CrossRefPubMed Drolet R, Bélanger C, Fortier M, Huot C, Mailloux J, Légaré D et al (2009) Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity 17:424–430CrossRefPubMed
17.
Zurück zum Zitat Xita N, Georgiou I, Chatzikyriakidou A, Vounatsou M, Papassotiriou G-P, Papassotiriou I et al (2005) Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem 51:416–423CrossRefPubMed Xita N, Georgiou I, Chatzikyriakidou A, Vounatsou M, Papassotiriou G-P, Papassotiriou I et al (2005) Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem 51:416–423CrossRefPubMed
18.
Zurück zum Zitat Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M (2001) Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. J Clin Endocrinol Metab 86:3772–3778CrossRefPubMed Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M (2001) Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. J Clin Endocrinol Metab 86:3772–3778CrossRefPubMed
19.
Zurück zum Zitat Telli MH, Yildirim M, Noyan V (2002) Serum leptin levels in patients with polycystic ovary syndrome. Fertil Steril 77:932–935CrossRefPubMed Telli MH, Yildirim M, Noyan V (2002) Serum leptin levels in patients with polycystic ovary syndrome. Fertil Steril 77:932–935CrossRefPubMed
20.
Zurück zum Zitat Guvenc Y, Var A, Goker A, Kemal Kuscu N (2016) Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. J Int Med Res 44:796–805CrossRefPubMed Guvenc Y, Var A, Goker A, Kemal Kuscu N (2016) Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. J Int Med Res 44:796–805CrossRefPubMed
21.
Zurück zum Zitat Kort DH, Kostolias A, Sullivan C, Lobo RA (2015) Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 31:152–155CrossRefPubMed Kort DH, Kostolias A, Sullivan C, Lobo RA (2015) Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 31:152–155CrossRefPubMed
22.
Zurück zum Zitat Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS (2006) Increased visfatin mRNA and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome (PCOS): parallel increase in plasma visfatin. J Clin Endocrinol Metab 91:5022–5028CrossRefPubMed Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS (2006) Increased visfatin mRNA and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome (PCOS): parallel increase in plasma visfatin. J Clin Endocrinol Metab 91:5022–5028CrossRefPubMed
23.
Zurück zum Zitat Lajunen TK, Purhonen AK, Haapea M, Ruokonen A, Puukka K, Hartikainen AL et al (2012) Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest 42:321–328CrossRefPubMed Lajunen TK, Purhonen AK, Haapea M, Ruokonen A, Puukka K, Hartikainen AL et al (2012) Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest 42:321–328CrossRefPubMed
24.
Zurück zum Zitat Kazama K, Usui T, Okada M, Hara Y, Yamawaki H (2012) Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 686:116–123CrossRefPubMed Kazama K, Usui T, Okada M, Hara Y, Yamawaki H (2012) Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 686:116–123CrossRefPubMed
25.
Zurück zum Zitat Yang H-Y, Ma Y, Lu X-H, Liang X-H, Suo Y-J, Huang Z-X, et al. (2015) The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome. Ann Endocrinol 76:620–627CrossRef Yang H-Y, Ma Y, Lu X-H, Liang X-H, Suo Y-J, Huang Z-X, et al. (2015) The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome. Ann Endocrinol 76:620–627CrossRef
26.
Zurück zum Zitat Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D (2004) Serum resistin leve in women with polycystic ovary syndrome. Fertil Steril 81:361–366CrossRefPubMed Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D (2004) Serum resistin leve in women with polycystic ovary syndrome. Fertil Steril 81:361–366CrossRefPubMed
Metadaten
Titel
The association between polycystic ovary syndrome, obesity, and the serum concentration of adipokines
verfasst von
S. Behboudi-Gandevani
F. Ramezani Tehrani
R. Bidhendi Yarandi
M. Noroozzadeh
M. Hedayati
F. Azizi
Publikationsdatum
01.08.2017
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 8/2017
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-017-0650-x

Weitere Artikel der Ausgabe 8/2017

Journal of Endocrinological Investigation 8/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.